Search

Your search keyword '"Spagnuolo, Vincenzo"' showing total 484 results

Search Constraints

Start Over You searched for: Author "Spagnuolo, Vincenzo" Remove constraint Author: "Spagnuolo, Vincenzo"
484 results on '"Spagnuolo, Vincenzo"'

Search Results

1. Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options—the ICONA Foundation cohort study

2. Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes

3. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

4. THU-402 Higher cardiovascular burden in people living with HIV (PLWH) with metabolic syndrome and history of HCV infection

8. Cancer in people with multidrug-resistant HIV.

9. Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.

10. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors

11. Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy

12. Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests

13. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

14. One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study.

15. Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors

16. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes

17. Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice

20. Correspondence.

21. 2408. Is Shorter Antibiotic Treatment Feasible in Patients with Cardiac Implantable Electronic Devices (CIED) Infections? Impact of Treatment Duration on 6-Month Recurrence and Mortality

22. Sexually transmitted infections in people with multidrug-resistant HIV

23. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: data from the ICONA cohort

26. Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry

28. Regaining virological suppression in a woman living with a six‐class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests.

30. Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting

31. Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir.

34. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

36. Inflammation burden score in multidrug-resistant HIV-1 infection

37. Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice

38. High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19

39. Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield

40. Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry

43. The propensity for long‐acting cabotegravir and rilpivirine every 2 months among HIV‐infected people eligible for treatment

44. Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization

45. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study

46. Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

48. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

49. Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice

50. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study

Catalog

Books, media, physical & digital resources